Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

NCT05027425 is registered in ClinicalTrials.gov with University of Cincinnati as lead sponsor.

NCT NCT05027425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05027425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
Lead sponsor
University of Cincinnati
Phase
Phase 2
Overall status
Terminated
Start date
December 7, 2021
Completion date
November 7, 2024
Enrollment
8 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cirrhosis, hepatocellular carcinoma, portal hypertension